Neurofibromatosis Type 1 in Genetic Counseling Practice: Recommendations of the National Society of Genetic Counselors

Heather B. Radtke · Courtney D. Sebold · Caroline Allison · Joy Larsen Haidle · Gretchen Schneider

Received: 22 March 2007 / Accepted: 27 March 2007 / Published online: 17 July 2007 © National Society of Genetic Counselors, Inc. 2007

Abstract The objective of this document is to provide recommendations for the genetic counseling of patients and families undergoing evaluation for neurofibromatosis type 1 (NF1) or who have received a diagnosis of NF1. These recommendations are the opinions of a multi-center working group of genetic counselors with expertise in the care of individuals with NF1. These recommendations are based on the committee’s clinical experiences, a review of pertinent English language medical articles, and reports of expert committees. These recommendations are not intended to dictate an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. These recommendations do not displace a health care provider’s professional judgment based on the clinical circumstances of an individual patient.

Keywords Neurofibromatosis type 1 · NF1 · Genetic counseling · Practice guidelines · National Society of Genetic Counselors · von Recklinghausen disease

Our geneticist convinced us that in reality nothing had changed with our daughter when we walked through the door. We just had more information. She convinced us that although life was uncertain, we need to make sure that our child was given the opportunity to reach her full potential, no matter what that might be. Medically, if we were out having fun prior to the diagnosis, then that shouldn’t change. We should continue to enjoy life and not let the information affect the child. In that sense, information can be harmful and NF will have already caused harm. I will say that we were still devastated, but her words helped us get through the process more quickly than if someone had just sat there and told us the facts and answered our questions. She set us out with goals in our life and a framework with which to use that information in our child’s best interest.

-Parent of a child with NF1, commenting on his experience with the genetic counseling process.
Purpose

The purpose of these guidelines is to serve as a comprehensive resource for health care professionals providing genetic counseling to patients and families undergoing evaluation for neurofibromatosis type 1 (NF1) or who have received a diagnosis of NF1. In this document, we review the diagnosis, natural history, and genetics of NF1. We suggest relevant items to be included in the genetic counseling session. Specific medical management recommendations will not be discussed in this document.

Disclaimer

These recommendations were approved in March 2007 by the National Society of Genetic Counselors (NSGC)—the leading voice, advocate and authority for the genetic counseling profession. This document is not intended to replace the judgment of an individual genetic counselor with respect to particular patients or special clinical situations and cannot be considered inclusive of all practices or exclusive of other practices reasonably directed at obtaining the same results. In addition, the practice of genetic counseling is subject to regulation by federal, state and local governments. In a subject jurisdiction, any such regulations will take precedence over this statement. NSGC expressly disclaims any warranties or guarantees, express or implied, and shall not be liable for damages of any kind, in connection with the information set forth in this document or for reliance on its contents.

Genetic counseling is a dynamic profession, which undergoes rapid change with the discovery of new genetic information and the development of new genetic tests and treatment options. Thus, NSGC will periodically review and, where appropriate, revise this statement as necessary for consistency with current practice information.

Objectives

The goals of these recommendations are to:

1. Review the history, epidemiology, and genetics of NF1.
2. Summarize the current understanding of the natural history of NF1.
3. Provide a framework for the genetic counseling sessions of individuals and families with NF1.
4. Present a list of resources for patients and families with NF1.

Materials and Methods

The NF1 Working Group was composed of genetic counselors with experience in various NF1 Clinics throughout the United States. MEDLINE, PubMed and Internet databases were searched (using the key words neurofibromatosis type 1, NF1, neurofibromin) to locate relevant English language medical papers published between 1966 and 2007. The literature was reviewed and evaluated according to the following categories outlined by the US Preventive Services Task Force (1995):

I. Evidence obtained from at least one properly designed randomized controlled trial.

II-1. Evidence obtained from well-designed controlled trials without randomization.

II-2. Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.

II-3. Evidence obtained from multiple time series, with or without the intervention.

III. The opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

The rating of supporting literature for this recommendation is Class III. Particular attention was paid to genetic counseling issues. Following the completion of the initial draft of the guidelines, the NF1 Working Group elicited opinions and feedback from noted medical experts in the field, as well as representatives of NF1 support and advocacy organizations (See “Patient Resources”). These recommendations were approved by the NSGC Board of Directors in March, 2007.

Overview of Neurofibromatosis Type 1

Historical Background

Over the centuries, NF1 has been known by many names, including peripheral neurofibromatosis, von Recklinghausen disease, and, erroneously, the “Elephant Man Disease.” The history of NF1 is briefly summarized in Table I.

Historically, there has been confusion regarding the relationship between neurofibromatosis types 1 and 2. It was initially thought that these two conditions represented different manifestations of the same underlying entity. In 1930, Garner and Frazier first suggested that individuals with only central nervous system tumors should be differentiated from those with other manifestations of the condition. Genetic linkage to two distinct loci confirmed that these two conditions were not only clinically but also etiologically distinct (Rouleau et al. 1987).

Another historical confusion is the belief that the “Elephant Man” had neurofibromatosis. Joseph Merrick had a debilitating disfigurement originally presumed to be NF. His life was originally documented by Treves in 1923.
Later, a play and a movie introduced this story to the public. Current knowledge suggests that Joseph Merrick had Proteus syndrome rather than NF (Tibbles and Cohen 1986). However, the repercussions of the initial presumption persist, and many families continue to be misinformed that NF1 is the “Elephant Man Disease.”

Epidemiology

NF1 is one of the most common genetic conditions with an estimated prevalence of 1 in 3,500 people (Huson et al. 1989; Poyhonen et al. 2000; Rasmussen and Friedman 2000). A distinct feature of the NF1 gene is the very high spontaneous mutation rate ($1 \times 10^{-4}$ per gamete per generation), which is about 100-fold higher than the typical mutation rate for a single locus. This high mutation rate cannot be accounted for strictly by the size of the gene (Upadhyaya and Cooper 1998). NF1 affects all races, ethnicities, and genders.

Diagnosis

Although the diagnosis of NF1 has historically been established by clinical evaluation, continued advances in the study of NF1 may lead to modification of diagnostic strategies. In recent years, advances in molecular testing offer another diagnostic approach.

Clinical Evaluation

Traditionally, NF1 has been a clinical diagnosis, based on a set of diagnostic criteria established in 1987 (NIH Consensus Development Conference 1988). These criteria are listed in Table II and are also available online: (http://consensus.nih.gov/1987/1987Neurofibromatosis064html.htm) (NIH Consens Statement Online 1987).

The appearance of many of the diagnostic manifestations of NF1 is age-dependent. This may make the diagnosis in a young child without a family history of the condition challenging. As a result, children may need to be followed for several years before the clinical diagnosis of NF1 can be confirmed. Approximately 90% of individuals with NF1 will have two or more diagnostic criteria by 6 years of age, 97% by age 8 and all do so by 20 years of age (DeBella et al. 2000; Korf 1992). The most common NF1 referral indication is multiple café-au-lait spots; however, not all children with café-au-lait spots will be diagnosed with NF1.

Molecular Testing

Genetic testing is clinically available and identifies approximately 95% of mutations in individuals that fulfill the clinical diagnostic criteria (Messiaen et al. 2000). Testing may be beneficial to individuals meeting only one of the diagnostic criteria or when the diagnosis is unclear. A positive DNA test result cannot predict the presence, age of onset, or severity of NF1 symptoms (See “Molecular Basis of Disease”). Likewise, a negative result, in the absence of a known familial mutation, cannot exclude the diagnosis.

Natural History

Phenotypic Variability

NF1 exhibits an extreme degree of inter- and intra-familial variability. Modifier genes may play a role in this variability (Szudek et al. 2002). One study estimated that two-thirds of individuals with NF1 are relatively mildly affected, not
requiring major surgery or having life-threatening problems (Carey et al. 1979). However, at the time this study was completed, many of the serious complications that are now known to be associated with NF1 had not yet been recognized. Therefore, this may represent an underestimate of the rate of serious complications of NF1.

Clinical Features

Table III lists the frequency and age of onset of common symptoms of NF1.

Café-au-lait Spots

Café-au-lait spots (CALS) are pigmented lesions proportionately darker than one’s skin color with uniform pigmentation and smooth borders. The presence of multiple CALS is one of the most well-recognized features of NF1. Ninety-nine percent of individuals with NF1 meet the CALS diagnostic criteria by 1 year of age (DeBella et al. 2000). In the newborn, typical CALS are oval-shaped lesions between 1 and 4 cm in diameter (Alper and Holmes 1983). As the child ages, the number and size of CALS may increase. In adults, CALS tend to fade and may be more difficult to identify.

Freckling

Another characteristic but innocuous finding of NF1 is freckling, which is present in over 90% of patients by 7 years of age (DeBella et al. 2000). The freckles are similar in color to café-au-lait spots but are much smaller and often occur in clusters (Friedman and Riccardi 1999). They are most commonly found in the axillary and inguinal regions, but they can also occur in other areas of skin-to-skin contact, such as the underside of the breast in female patients, between skin folds in obese patients, and on the back of the neck.

Lisch Nodules

Lisch nodules are a common feature of NF1. Lisch nodules are pigmented hamartomas of the iris that do not affect vision. They are typically not present at birth, but they develop during childhood. More than 95% of individuals with NF1 have Lisch nodules by the age of 20 (Flueler et al. 1986; Huson et al. 1987; Lubs et al. 1991). Slit lamp examination by an ophthalmologist is necessary to determine the presence or absence of Lisch nodules as well as the distinction between these and iris nevi, which are not associated with NF1 (Friedman and Riccardi 1999).

Optic Pathway Gliomas

Optic pathway gliomas (OPG), or pilocytic astrocytomas of the optic nerve, are the most common central nervous system tumors seen in NF1 and typically present in early childhood (less than 6 years of age) (Listernick et al. 1999; Singhal et al. 2002). It has been estimated that up to 70% of all OPGs are related to NF1 (Listernick et al. 1999). OPGs may be either unilateral or bilateral and may involve the optic nerve, the chiasm, or both. Approximately 15% of NF1 patients will develop an OPG, half of whom have no clinical symptoms (Korf 2000; Listernick et al. 1994; DeBella et al. 2000; Evans et al. 2002; Korf et al. 2005; Levy et al. 2005; Listernick et al. 1999)

| Symptoms                                      | Typical age at presentation | Frequency       |
|-----------------------------------------------|-----------------------------|-----------------|
| Café-au-lait spots                            | Early presentation          | 99%             |
| Freckling (axillary, inguinal)                | Between 3 and 5 years       | >90%            |
| Lisch nodules                                 | Late childhood              | 95%             |
| Cutaneous neurofibromas                       | Variable; may see increase in size and number during adolescence and pregnancy | 0–9 years 14%   |
|                                              |                             | 10–19 years 44% |
|                                              |                             | 20–29 years 85% |
|                                              |                             | >30 years 95%   |
| Diffuse plexiform neurofibromas               | Congenital; manifest early in life | 25%             |
| Tibial dysplasia and/or sphenoid dysplasia    | Typically visible clinically by 1 year | 1–4% tiibial   |
|                                              |                             | 3–7% sphenoid   |
| Learning disabilities                         | May not be identified until school age | 20–50%; MR uncommon (4.8–11%) |
| ADHD                                          | Childhood                   | 20–40%          |
| Optic nerve glioma                            | Childhood; may be asymptomatic | 15%             |
| Malignant peripheral nerve sheath tumor (MPNST) | Average age at diagnosis is 28 years | 4–13%          |

(DeBella et al. 2000; Evans et al. 2002; Korf et al. 2005; Levy et al. 2005; Listernick et al. 1999)
Skeletal Findings

Scoliosis is the most common skeletal finding in NF1 with an estimated frequency ranging from 10 to approximately 25% (Akbarnia et al. 1992; Crawford and Schorry 1999; Friedman and Birch 1997; Riccardi 1999b; Vitale et al. 2002). The scoliosis can be either dystrophic or non-dystrophic (Alwan et al. 2005). The dystrophic type of scoliosis is associated with bony abnormalities evident on radiographic films and tends to be more severe with rapid progression. This form of scoliosis typically presents between 6 and 10 years of age, and, if not present by 10 years, is unlikely to develop (Riccardi 1999b). The non-dystrophic form of scoliosis has no apparent bony abnormalities and has findings similar to idiopathic scoliosis in individuals without NF1; it presents during adolescence and tends to be less severe. Kyphoscoliosis may also develop (Alwan et al. 2005). Occasionally, these spinal abnormalities may be caused by an underlying neurofibroma.

Sphenoid dysplasia is present in 3–7% of NF1 patients and typically presents as a unilateral defect (Riccardi 1999b; Alwan et al. 2005). Over 50% of cases of sphenoid dysplasia are associated with NF1. The lesions are usually asymptomatic and are diagnosed by skull radiographs or CT scans (Alwan et al. 2005). In rare instances, progression of a lesion may lead to medical complications such as enophthalmos and herniation of the brain into the orbit (Riccardi 1999b).

Lesions of the long bones are another feature of NF1 with a prevalence of 1–4% (Crawford and Schorry 1999; Friedman and Birch 1997; Vitale et al. 2002). The tibia is most frequently involved, although other long bones may also be affected (Ali and Hooper 1982; Alldred 1963; Floyd and Percy-Lancaster 1987; Gregg et al. 1982; Keret et al. 2000; Riccardi 1999b). Congenital pseudarthrosis, or “false joint” abnormality, occurs in 1–2% of NF1 patients (Friedman and Birch 1997; Riccardi 1999b). These lesions are often detected during infancy or early childhood and present as bowing or fracturing of the affected bone (Alwan et al. 2005). Other potential abnormalities of the long bones include changes associated with a plexiform neurofibroma or localized lytic defects (Riccardi 1999b).

NF1 patients also have an increased risk for osteoporosis and osteopenia. (Kuorilehto et al. 2005). Other skeletal anomalies found in NF1 patients may include pectus deformities, genu varum, and genu valgum (Riccardi 1999b).

Neurofibromas

Neurofibromas (NFs) are benign tumors that can occur anywhere in the body. They most commonly develop along peripheral nerves or less frequently in the deep nerves. Neurofibromas are typically multicellular in origin, composed of Schwann cells, axons, fibroblasts, mast cells, endothelial cells and perineurial cells (Peltonen et al. 1988). Pruritis, or itching, is a somewhat common feature of NF1 and when localized, often precedes the development of cutaneous neurofibromas.

NFs can be classified into different types (Friedman and Riccardi 1999; Korf and Rubenstein 2005):

1. Discrete Neurofibromas

Discrete NFs are benign tumors that arise from a single site on a peripheral nerve. They are rarely present at birth, often appearing just before the time of puberty (Dugoff and Sujansky 1996; Korf and Rubenstein 2005). The number of dermal neurofibromas tends to increase with age and varies widely between individuals. They may increase in size and number during pregnancy. Discrete NFs are encapsulated; they may grow in size and press on other tissues, but will not invade them.

**Discrete Cutaneous Neurofibromas.** Discrete cutaneous NFs usually protrude above the skin and are soft and fleshy. They may be flesh-colored, pink or purple. They may be sessile or pedunculated. They often initially appear on the chest, abdomen and back. Typically, these NFs are not painful, but may cause pruritis and often have a significant cosmetic burden.

**Discrete Subcutaneous Neurofibromas.** Discrete subcutaneous NFs develop along nerves contained in deeper body tissue under the epidermis. They are usually firm and rubbery to palpation and can be distinguished from cutaneous neurofibromas because the skin can be moved over the nodule. These tumors may present clinically as beadlike nodules along the length of the nerve and they range in size from pea-sized to several centimeters. They may be painful or tender. Tumors in deeper nerves can compress a nerve root, causing radicular pain, weakness or loss of sensation.

2. Plexiform Neurofibromas

Plexiform NFs (PNFs) grow along the length of a peripheral nerve sheath. They are non-encapsulated and therefore may grow into healthy tissue and interfere with normal development of tissue or bone. These tumors tend to be supported by a network of blood vessels and therefore are usually difficult to surgically remove. Most PNFs are benign, but there is a risk
for transformation to malignant peripheral nerve sheath tumors (MPNST) (See “Tumors and Malignancy”).

**Diffuse Plexiform Neurofibromas.** Diffuse PNFs are usually congenital, but may not be recognized until they increase in size or are found incidentally. They may spread out from the area of origin and develop numerous extensions that infiltrate extensively into adjacent normal tissues, making complete surgical removal difficult. They may also engulf nerves. The tumors can occur superficially, in deep tissues, or a combination thereof. With superficial involvement, skin may be thickened, redundant, and/or hyperpigmented. There may also be thick, coarse hair or localized hypertrophy over the affected area. Diffuse PNFs are described as having a “bag of worms” feel on palpation and most often develop in the head, neck and abdomen. They typically grow most rapidly during childhood, although they sometimes increase during adolescence and pregnancy.

**Nodular Plexiform Neurofibromas.** Nodular PNFs are less common than diffuse PNFs and are discrete lesions that arise in peripheral nerve trunks. The most frequent site of involvement is along the spinal nerves. The tumors are typically referred to as Unidentified Bright Objects (UBOs) or “NF spots.” They exert no mass effect and are not observed on CT scan. They often resolve with time and are rarely seen in NF1 patients over the age of 20 (Aoki et al. 1989). Some researchers have suggested a connection between the presence of UBOs and lower IQ, language skills, visuospatial functioning and academic achievement (Denckla et al. 1996), although this has not been found in other studies (Friedman and Riccardi 1999).

**Growth**

Individuals with NF1 tend to be below average in height and true short stature (<10th percentile) occurs in more than 40% of adults with NF1 (Carmi et al. 1999). One study found growth hormone deficiency in 3 of 122 children, although this does not appear to be the cause of short stature in most patients with NF1 (Cnossen et al. 1997).

Macrocephaly, either relative or absolute, is present in 29–45% of individuals with NF1 and usually develops during childhood (Clementi et al. 1999; Friedman and Riccardi 1999; Riccardi 1999b; Szudek et al. 2000). Rarely, underlying hydrocephalus is identified (Friedman and Riccardi 1999).

**Onset of Puberty**

Most individuals with NF1 undergo normal pubertal development (Friedman and Riccardi 1999). However, in approximately 1–4% of patients, puberty may be premature or delayed (Friedman and Birch 1997). Precocious puberty typically results from an optic chiasm glioma or other tumor proximal to the region of the hypothalamus (Friedman and Riccardi 1999; Habiby et al. 1995).

**Pregnancy and NF**

Although NF1 appears to have no intrinsic effect on fertility, negative pregnancy outcome has been reported (Friedman and Riccardi 1999). Early reports suggest a significant increase in complications including intrauterine growth retardation, preterm labor, and stillbirth (Belton et al. 1984; Edwards et al. 1983; Weissman et al. 1993). However, these findings are controversial, and more recent studies suggest that most pregnancy outcomes for healthy women with NF1 are normal, although there appears to be an increased need for cesarean-sections (Dugoff and Sujansky 1996). Pregnancy is frequently associated with an exacerbation of existing maternal symptoms as well as the new presentation or rapid increase in tumors and hypertension (Ansari and Nagamani 1976; Dugoff and Sujansky 1996; Swapp and Main 1973). A subsequent decrease in the size of the exacerbated neurofibromas in the postpartum period is sometimes seen (Dugoff and Sujansky 1996).

---

Seizures

Although not common, there are some studies that suggest an increased frequency of seizures (range 3.5–7.3%) in NF1 (Friedman and Riccardi 1999; North 1993). The seizures that are suggested to be associated with NF1 do not differ from those seen in the general population. When not associated with an intracranial lesion or stenosis, these seizures are generally well-controlled with routine antiepileptic drugs (Gutmann 1999).

**Headaches**

Individuals with NF1 have an increased frequency of headaches. These range from a mild “tension” headache to a true migraine (Riccardi 1981). Although common, a new onset of headaches or ones that are atypical for the patient and/or accompanied by neurologic deficits, may warrant investigations for other causes including brain tumors, pheochromocytomas or cerebrovascular etiologies (Friedman and Riccardi 1999; Riccardi 1981).

**UBOs**

Cranial MRI scans in NF1 patients often show focal areas of high signal intensity on T2 or FLAIR weighted images. They
Cardiovascular Findings

Hypertension is a common finding in individuals with NF1. The incidence of hypertension increases with age and can lead to heart attack, stroke, kidney failure, and other medical problems. In most cases, the hypertension is essential. However, less common causes of hypertension include renal artery abnormalities, pheochromocytomas, and, in rarer instances, aortic coarctations or brain tumors (Friedman 1999a).

Congenital heart defects have been reported in patients with NF1 with an estimated frequency between 0.4 and 6.4% (Carey et al. 1979; Crowe et al. 1956; Lin et al. 2000; Schorry et al. 1989). The most common cardiac abnormality is valvar pulmonic stenosis (Friedman and Birch 1997; Lin et al. 2000). This abnormality has been described in individuals with the Watson and the NF1-Noonan phenotypes as well as individuals with a large gene deletion (See “Variants of NF1”); however, the incidence of pulmonic stenosis is also increased in patients with NF1 without these variant phenotypes. Coarctation of the aorta and other heart defects have also been reported (Friedman and Birch 1997; Lin et al. 2000). Several reports have identified NF1 patients with hypertrophic cardiomyopathy. Current evidence is insufficient to determine whether these reflect manifestations of NF1 or are simply coincidental.

Vasculopathies are a well-recognized cardiovascular complication of NF1 (Friedman 1999a). They may be peripheral or cerebrovascular. The specific types of lesions include stenoses, dilations, aneurysms, and fistulas (Friedman et al. 2002). Arterial involvement is most common, although venous involvement has also been reported (Lehrnbecher et al. 1994). These lesions frequently occur in the renal arteries, but may also occur in the cerebral or visceral arteries (Criado et al. 2002; Serleth et al. 1998; Westenend et al. 1994). The exact frequency of vasculopathy in patients with NF1 is unknown and many patients with vasculopathy remain asymptomatic throughout their lives (Friedman et al. 2002). Symptomatic vascular lesions are most commonly detected in childhood or early adulthood and may be identified during a pregnancy (Friedman et al. 2002; Pilmore et al. 1997). A study by Rosser et al. (2005) identified a cerebrovascular abnormality in 2.5% of patients with NF1. These abnormalities may present with neurological symptoms secondary to cerebral ischemia (Friedman et al. 2002).

Pruritis

Pruritis, or chronic itching, is a relatively common feature of NF1. It may be generalized or restricted to a certain area of the body. When localized, the itching may precede the development of cutaneous neurofibromas. The itching is thought to be related to the large amount of mast cells in neurofibromas and is often relieved by anti-histamines (Korf and Rubenstein 2005; Riccardi 1981).

Tumors and Malignancy

The malignancy rates in individuals with NF1 are higher than the general population risk, though precise risk estimates vary. Literature reports suggest that the risk for malignancy in individuals with NF1 is 5–15% higher than the general population risk (Walker et al. 2006). On average, the onset of malignancy in NF1 patients appears to be earlier than the general population (Kim et al. 2002; Walker et al. 2006). A prospective study by Walker et al. suggests that the increased malignancy rate comes primarily from a higher incidence of central nervous system and connective tissue malignancies (Walker et al. 2006).

Malignant Peripheral Nerve Sheath Tumors

Approximately 4–13% of patients with NF1 will develop a malignant peripheral nerve sheath tumor (MPNST), also called malignant schwannoma or neurofibrosarcoma (Evans et al. 2002; Korf 2000; Levy et al. 2005). The most common locations of these tumors in NF1 patients are the abdominal paraspinal region, the extremities, and the head and neck regions (Levy et al. 2005). Approximately 20–50% of patients with MPNSTs also have NF1 (Evans et al. 2002; Korf 2000; Levy et al. 2005). Compared to individuals without NF1, individuals with NF1 tend to be diagnosed with an MPNST at a younger age and have a poorer prognosis. Most of the time, MPNSTs in NF1 are associated with an underlying plexiform neurofibroma (Evans et al. 2002; Levy et al. 2005; Korf 2000). While plexiform neurofibromas may be very large tumors, the malignant component of the tumor may be very small and can easily be missed by a single biopsy. Symptoms commonly reported by patients with an MPNST include pain, enlarging tumor mass, and neurologic symptoms (Korf 2000).

Pheochromocytomas

Pheochromocytomas are catecholamine-secreting tumors that occur most often in the adrenal gland. They occur in approximately 0.1–5.7% of NF1 patients. In the majority of cases, the NF1-related pheochromocytoma will be a single, unilateral tumor (84%). Roughly 10% of patients will have a bilateral pheochromocytoma and a small percentage (6%) will have an extra-adrenal pheochromocytoma (Walther et al. 1999). Pheochromocytomas often lead to increased production of adrenaline which may cause hypertension and a variety of other associated symptoms such as headaches, cardiac palpitations, diaphoresis and tremors. They may become metastatic. (Walther et al. 1999).
**Gastrointestinal Tumors**

There is a wide spectrum and diverse nature of tumors that occur along the gastrointestinal (GI) tract in NF1 patients. Neurofibromas are the most common tumor of the gastrointestinal tract in patients with NF1, however most of these are benign and asymptomatic. When symptomatic, abdominal pain, constipation and bleeding are the most common presenting symptoms. The incidence of gastrointestinal carcinoids is higher in NF1 patients than in the general population; however, the malignancy rate is comparable between the two groups (Levy et al. 2005). Gastrointestinal stromal tumors (GIST) are associated with NF1. Contrary to non-NF1 patients, NF1-related GIST occur primarily in the small intestine and typically present as either multiple tumors or are associated with other GI neoplasms (Levy et al. 2004).

**Leukemia and Lymphoma**

There have been several reports suggesting an increased risk for acute lymphoblastic leukemia, non-Hodgkin lymphoma and juvenile myelomonocytic leukemia (JMML) in NF1 (Stiller et al. 1994; Zvulunov et al. 1995). As many as 14% of individuals with JMML have NF1 (Niemeyer et al. 1997). However, the risk of an individual with NF1 developing JMML is low. (Gutmann and Gurney 1999). An association between leukemia and the cutaneous finding of juvenile xanthogranulomas (JXG) has been suggested, but this association has not been well-established (Cambiaghi et al. 2004; Morier et al. 1990).

**Gliomas**

Optic gliomas are seldom malignant and are discussed earlier in this document. Other than optic gliomas, individuals with NF1 are at risk for other types of gliomas, including cerebellar astrocytomas, ependymomas, third ventricle astrocytomas, cerebral astrocytomas, brain stem gliomas, and spinal cord tumors. The risk of malignant transformation in these tumors in NF1 patients was found to be higher than in those without NF1 (Ilgren et al. 1985).

**Embryonal Tumors**

Rhabdomyosarcomas are seen with disproportionately high frequency in individuals with NF1. An association of NF1 with neuroblastoma and Wilms tumor has been suggested but has not been confirmed (Korf 2000; Levy et al. 2005).

**Breast Cancer**

Questions have been raised regarding a potentially increased risk for breast cancer in individuals with NF1 due to the possible role of neurofibromin in some breast cancers (Guran and Safali 2005). This concern has been further supported by a prospective study suggesting an increased risk for early onset-breast cancer among women with NF1 (Walker et al. 2006). Additional data and larger studies are necessary to determine whether the breast cancer risk in individuals with NF1 is truly increased.

**Miscellaneous Tumors**

A variety of other tumors occur in NF1 including leiomyosarcomas, ganglioneuromas and adenocarcinomas (Levy et al. 2005).

**Cognitive Phenotype**

The vast majority of individuals with NF1 have intelligence within the normal range. However, there is a documented leftward shift in the IQ curve, as well as an increased incidence of both mental retardation (MR) and learning disabilities as compared to the general population (Barton and North 2004; Eliason 1986; Fermer et al. 1996; Mazzocco et al. 1995). The incidence of MR in the NF1 population is estimated to be between 4.8 and 11% (Dilts et al. 1996; Fermer et al. 1996; Hyman et al. 2005; North et al. 1995; Wadsby et al. 1989). Large NF1 gene deletions are a frequent finding in patients with MR, and patients with such deletions tend to exhibit a more severe phenotype overall (Ainsworth et al. 1997) (See “Variants of NF1”). Accordingly, MR is not typically expected in individuals without the deletion. The occurrence of MR in a patient with NF1 without a full gene deletion may warrant further evaluations to rule out other more common causes of MR, such as chromosomal duplications/deletions, and fragile X syndrome.

Learning disabilities are a much more common occurrence in NF1. Historically, most studies have estimated the incidence of learning disabilities to be between 40 and 60%, although the criteria for defining a “learning disability” have varied (Hyman et al. 2005; Kayl and Moore 1995; North 1999; Ozonoff 1999; Samuelsson and Axelsson 1981; Stine and Adams 1989; Wadsby et al. 1989). The Diagnostic and Statistical Manual of Mental Disorders IV (DSM IV) defines a specific learning disability as “the achievement on standardized tests that is more than two standard deviations below that expected for the individual’s level of intelligence” (American Psychiatric Association 2000). Using this definition, a study by Hyman et al. (2005) examined a cohort of 81 children with NF1, in which 81% of individuals showed some sort of cognitive impairment, but only 25% of individuals met the DSM IV diagnostic criteria for learning disabilities when controlling for IQ. Thus, some individuals with NF1 do not qualify for a formal diagnosis of a learning disability but will still
require intervention for other neuropsychological deficits. These deficits can include but are not limited to visuospatial skills, executive function, expressive and receptive language, social skills and motor coordination (Barton and North 2004; Chapman et al. 1996; Dilts et al. 1996; Ferner et al. 1996; Hyman et al. 2005; Johnson et al. 1999; Mazzocco et al. 1995; North et al. 1994, 1995, 2002; Varnhagen et al. 1988; Zoller et al. 1997).

Several studies have suggested a frequency of attention deficit disorder (ADD) with or without hyperactivity in approximately 30–40% of the NF1 population (Bawden et al. 1996; Cutting et al. 2000; DeWinter et al. 1999; Hyman et al. 2005; Kayl and Moore 1995).

In summary, the cognitive phenotype of NF1 is complex, variable, and unpredictable, and can include a wide range of learning disabilities, other neuropsychological deficits, and less often, mental retardation. Formal neuropsychological evaluation can help elucidate the specific challenges of an individual with NF1 to allow for appropriate intervention. Intervention is based on the presenting cognitive features, and these are managed in the same way as they would be in the non-NF1 population.

Life Expectancy

Individuals with NF1 are predicted to have a lifespan of approximately 15 years less than that seen in the general population (Rasmussen et al. 2001; Zoller et al. 1995). Khosrotehrani et al. (2005) reviewed data on 703 NF1 patients. The major cause of death in this population was malignancy. The second major cause was tumor-related neurological complications, and less frequent were vascular complications and accidents, suicide or causes of death that were indeterminate. Other reports demonstrate that cardiovascular disease is a frequent cause of premature death in individuals with NF1, and that myocardial infarction and cerebrovascular accidents occur at a younger than expected age among NF1 patients (Friedman et al. 2002; Zoller et al. 1995). Complications from surgery also may lead to a decreased life span (Korf and Rubenstein 2005).

Molecular Basis of Disease

The elucidation of the molecular basis of NF1 began in 1990 when the gene, *NF1*, was identified and the protein product, neurofibromin, were characterized (Cawthon et al. 1990b; Wallace et al. 1990). The *NF1* gene, located at 17q11.2 is approximately 350 kb in size and contains 60 exons. Within the *NF1* gene are three additional genes contained within an intron, which are transcribed in the opposite direction (Cawthon et al. 1991, 1990a; Mikol et al. 1990). The protein, neurofibromin, contains 2,818 amino acids.

The various functions of neurofibromin are still being investigated. It appears to serve a tumor suppressor function within the Ras signaling pathway (Zhu and Parada 2001). Typically, neurofibromin inactivates Ras by stimulating its conversion from Ras-GTP to Ras-GDP, thus controlling cell proliferation. However, when neurofibromin is abnormal or absent, Ras remains active and promotes cell proliferation and tumor growth. This is thought to be the mechanism responsible for the formation of tumors associated with NF1. It is also thought that abnormalities in this pathway contribute to the occurrence of learning disabilities (Korf and Rubenstein 2005).

To date, hundreds of mutations in the *NF1* gene have been identified, many of which are unique to an individual or family (Messiaen et al. 2003). Mutations identified include deletions, insertions, splice site mutations, amino acid substitutions, full gene deletions and chromosomal rearrangements. In the majority of cases, the mutation results in a truncated protein. A majority of molecular studies have not identified a strong genotype–phenotype correlation. (Rasmussen et al. 1998; Upadhya et al. 1998). However, in 2007, Upadhya et al. identified 21 patients with an atypical presentation and a 3-bp in-frame deletion in exon 17. All patients lacked cutaneous neurofibromas or clinically obvious plexiform neurofibromas. Other exceptions that demonstrate a possible genotype–phenotype correlation include some of the NF1 variants, including Spinal NF, NF-Noonan syndrome and individuals with deletions of the entire *NF1* gene. (See “Variants of NF1”).

There appears to be a parent-of-origin effect on the types of *de novo* mutations that arise in the *NF1* gene, with gene deletions being more frequent on the maternally derived chromosome and other types of mutations occurring preferentially on the paternally derived chromosome (Ainsworth et al. 1997; Stephens et al. 1992; Upadhya et al. 1998).

It should be noted that although NF1 is common, no convincing evidence of homozygous NF1 mutations have been reported, suggesting that at least one functional NF1 allele is essential in early fetal development (Friedman 1999b). This is further supported by the fact that homozygosity for NF1 mutations in mice leads to abnormal heart development and mid-gestation embryonic lethality (Jacks et al. 1994).

Differential Diagnosis

Individual signs and symptoms of NF1 can be seen in the absence of other clinical findings. Isolated tumors, including optic gliomas and neurofibromas, are well documented, although Lisch nodules are rarely seen outside of the NF1 spectrum. The presence of one or two CALS is fairly common in the general population; however, having multiple (three or more) CALS is noted in less than 1%
of children without other features of a genetic condition (Tekin et al. 2001). The diagnosis of NF1 is subsequently confirmed in a majority of these patients (Fois et al. 1993; Korf 1992). Some individuals with red hair, fair skin, and, often, Irish ancestry are referred to clinics to rule out NF1 due to multiple CALS. These CALS are paler and more irregular than typical NF1 CALS. It is unclear whether this is an extremely mild variant of NF1 or a normal pigmented variation (Schneider and Korf 1996).

Several conditions have features that overlap with NF1. See Table IV.

Variants of NF1
Segmental Neurofibromatosis

Clinical findings of NF1 that are confined to one or more well-circumscribed regions of the body have been described in many individuals. This entity is known as “segmental NF.” Typically, these manifestations do not encompass the entire clinical spectrum of NF1 and may include only dermatologic findings and/or neurofibromas. Ophthalmologic findings are seldom observed (Ruggieri et al. 2004). Usually, a mild clinical course is anticipated for those patients who present with only pigmentary features. However, studies looking at long-term outcomes of these patients are very limited. Therefore counseling patients about clinical prognosis based on the assumed presence of a mutation in a mosaic state must be undertaken with caution.

It is believed that segmental NF1 is caused by a post-zygotic mutation in the NF1 gene. Tischert et al. (2000) reported the first molecular evidence of this phenomenon. The timing of the post-zygotic event is believed to determine the extent of involvement. Mutations arising early in embryologic development may result in a more widespread mosaicism that may appear as classic NF1 (Colman et al. 1996). A milder phenotype presenting as patchy distribution, smaller segment involvement, or isolated findings, may be the result of mutations arising later in embryologic development.

Providing an accurate risk assessment for the offspring of an individual with segmental NF1 presents a great challenge. There have been reports of individuals with segmental NF1 having children with classic NF1 (Oguzkan et al. 2004; Poyhonen et al. 2000). Since individuals with segmental NF1 are presumed to have some proportion of cells that harbor an NF1 gene mutation, they should be counseled that the risk to their offspring for classic NF1 could be as high as 50%, though it is likely to be considerably lower. Lymphocyte molecular testing in segmental NF may not be informative as the sample may not include the affected region or cells. However, for individuals who have had informative molecular confirmation in the affected cells, prenatal genetic testing for that mutation could be pursued in future pregnancies.

Spinal Neurofibromatosis

A subset of patients with NF1 has a variant in which their tumors are primarily localized to the spinal nerve roots. These individuals exhibit variable skin manifestations. This variant is referred to as spinal neurofibromatosis (SNF). The hallmark of this condition is multiple bilateral symmetrical enlargement of the nerve root on the spine (Korf et al. 2005; Kluwe et al. 2003). Cord compression is a frequent complication in SNF (Korf et al. 2005). In contrast, spinal cord tumors associated with clinical symptoms are uncommon in classic NF1, affecting less than 7% of patients (Kluwe et al. 2003; Von Deimling et al. 1995). Lisch nodules may or may not be present. The diagnosis of spinal neurofibromatosis by physical examination alone can be difficult, as individuals can be affected and not meet diagnostic criteria for the classic form of NF1. Most patients with SNF will have a variable number of CALS, but even in adults, the dermal neurofibromas may not be present (Korf et al. 2005). Spinal neurofibromatosis is also inherited in an autosomal dominant fashion and appears to be associated with mild mutations, such as missense, nonsense, or splicing mutations in the NF1 gene (Kluwe et al. 2003).

NF-Noonan Syndrome

Noonan syndrome is characterized by short stature, characteristic facial features, a webbed neck and congenital heart disease (most commonly pulmonic stenosis). In 1985, Allanson et al. first reported the concurrence of NF1 and Noonan syndrome (NFNS). In subsequent years, controversy has remained as to whether NFNS represents a variable manifestation of either NF1 or Noonan syndrome; a chance occurrence of two common genetic disorders; or a distinctive clinical entity (Carey et al. 1995). De Luca et al. (2005) identified NF1 mutations in 16/17 patients with the NFNS phenotype. They found an increased prevalence of in-frame mutations involving exons 24 and 25 of the NF1 gene. No mutations in PTPN11, the gene most commonly associated with Noonan syndrome, were observed, suggesting that most cases of NFNS are due to mutations within the NF1 gene.

Watson Syndrome

Watson syndrome is characterized by pulmonic stenosis, multiple café-au-lait spots, and decreased IQ in addition to other various manifestation of NF1 (Allanson et al. 1991; Leao and da Silva 1995; Watson 1967). Linkage analysis, as well as identification of a gene deletion in one patient, support the hypothesis that this is an allelic variant of NF1 (Allanson et al. 1991; Upadhyyaya et al. 1992).
| Condition and gene (if known) | Overlapping features | Distinguishing features |
|--------------------------------|----------------------|------------------------|
| **Neurofibromatosis type 2 (NF2)** | CALS<br>Dermal and spinal cord tumors<br>Autosomal dominant | Pathology of tumors is more often schwannoma, meningioma<br>Vestibular schwannomas (acoustic neuromas) leading to deafness in mid-adulthood<br>Juvenile posterior subcapsular cataract<br>CALS do not meet NF1 diagnostic criteria |
| **LEOPARD Syndrome (Lentigines, Electrocadiographic abnormalities, Ocular Abnormalities, Pulmonic Stenosis, Abnormal Genitalia, Retardation of Growth and Deafness) (PTPN11)** | CALS and hyperpigmented lesions<br>Pulmonic stenosis<br>Autosomal dominant | Deafness<br>Multiple lentigines |
| **McCune–Albright Syndrome (GNAS1)** | CALS<br>Premature puberty | Polyostotic fibrous dysplasia<br>Endocrine abnormalities such as sexual precocity, hyperthyroidism, hyperparathyroidism<br>CALS are atypical—fewer in number, larger in size and have irregular margins<br>Sporadic (only compatible with life when in the mosaic state) |
| **Bannayan–Riley–Ruvalcaba Syndrome (PTEN)** | CALS<br>Multiple tumors<br>Macrocephaly<br>Learning problems<br>Autosomal dominant | Subcutaneous tumors are usually lipomas or hemangiomas<br>Polyposis of colon<br>Pigmentary changes of penis in males |
| **Multiple Lipomas** | Subcutaneous tumors<br>Autosomal dominant | Tumors are lipomas<br>No other features of NF1 |
| **Proteus Syndrome (PTEN)** | CALS<br>Hemihypertrophy, Subcutaneous tumors<br>Overgrowth of limbs<br>Learning disabilities | Epidermal nevi<br>Tumors are lipomas, lymphangiomas, and hemangiomas<br>Bony abnormalities including: prominences of skull, macrodactyly and hyperostosis<br>Soft tissue hypertrophy may appear as gyriform especially over plantar surfaces of feet<br>Sporadic |
| **Tuberous Sclerosis (TSC1; TSC2)** | CALS<br>Seizures<br>Learning problems<br>Behavior problems/ADHD<br>Autosomal dominant | Additional dermatologic findings including: ash leaf spots, shagreen patches<br>Pits in dental enamel<br>Cardiac rhabdomyoma<br>Angiomyolipomas of kidneys<br>Glioma/angioma lesions in cortex and white matter (“tubers”) |
| **Familial Multiple CALS** | CALS<br>Autosomal dominant | No other features of NF1 |
| **Schwannomatosis (INI1)** | Multiple tumors | Schwannomas of cranial, spinal or peripheral nerves<br>No other features of NF1<br>Mostly sporadic, though some reports of autosomal dominant inheritance |
| **Multiple Endocrine Neoplasia, Type IIB (RET)** | CALS<br>Tumors including pheochromocytoma<br>Autosomal dominant | Tumors usually involve the endocrine system<br>Marfanoid habitus |
Approximately 4–5% of NF1 patients have deletions of the entire NF1 gene. (Kluwe et al. 2004). The phenotype in these patients tends to be more severe, with an earlier onset of neurofibromas and the presence of mental deficiency, variable dysmorphic features and other congenital anomalies. (Kayes et al. 1994; Wu et al. 1995; Rasmussen et al. 1998). In addition, some of these individuals appear to have connective tissue abnormalities such as mitral valve prolapse and joint laxity. (Mensink et al. 2006). A study by De Raedt et al. suggested that the risk of MPNSTs is higher in this group of patients than in individuals with other types of mutations (De Raedt et al. 2003).

Ongoing Research

Research in NF1 is concentrated on the underlying causes of the various symptoms of the condition as well as potential therapies and treatments. Current studies are listed on the Children’s Tumor Foundation webpage (http://www.ctf.org), the Neurofibromatosis, Inc. webpage (http://www.nfinc.org), and at http://www.clinicaltrials.gov. Active areas of investigation include genotype–phenotype correlations; the role of modifier genes; etiology of extensive phenotypic variability; neurodevelopmental issues; and treatments for neurofibromas and other tumors.

Genetic Counseling

Contracting

As with other genetic counseling indications, ascertaining the family’s understanding of the reason for the visit as well as their primary questions and concerns, and mutually developing a plan to address these concerns, are key components of establishing rapport in the NF counseling process (Weil 2000).
nancy risks should be discussed in the context of the general population’s cancer risk, which is approximately 41% (http://seer.cancer.gov/csr/1975_2003/results_merged/topic_lifetime_risk.pdf).

d. Address concerns and fears regarding the variable and unpredictable natural history of NF1. Explain that the majority of individuals lead productive lives, meaning that they are able to attend school, be employed and live independently. Providing the family with a list of concerning symptoms (See “Education”) can be helpful in giving the family a sense of control when they are experiencing anxiety about the unpredictable nature of NF1.

e. Assess perception of the impact of NF1 on the individual’s daily life, with a focus on cosmetic and medical concerns. Wolkenstein et al. (2001) found that quality of life in adults with NF1 was negatively correlated with the visibility of the manifestations of NF1.

f. Discuss family’s concerns regarding labeling and self-fulfilling prophecies. Many parents are concerned that the diagnosis of a genetic condition will lower a child’s self-expectations or the expectations of others for the child.

g. Assess the family’s knowledge and perception of the Elephant Man. Despite the current belief that “The Elephant Man” did not have NF1, older literature and resources often refer to NF1 as the disease of “The Elephant Man.” Families of patients with NF1 may still be affected by the association of NF1 with the difficult life of Joseph Merrick (Ablon 1995).

h. Elicit the individual’s experiences at school, work and other social situations. In addition to the learning disabilities, many NF1 patients have difficulty with social skills. This may also be impacted by the co-occurrence of ADHD.

i. Be aware of issues regarding counseling an individual with a learning disability. In familial cases of NF1, a parent may also have a learning disability. This may affect an individual’s understanding and perception of the disorder, their ability to recognize or cope with the potential medical issues, and their comprehension of the genetic implications for future offspring. In these families, it is particularly important to determine the level of understanding and adjust the counseling session to reflect the family’s comprehension level. It is also important to keep in mind that individuals with learning disabilities may prefer alternate methods of receiving information and may benefit from reinforcement at follow-up visits (Finucane 1998).

j. As indicated, assist the family in navigating the complexities of special education and/or other interventional services. Many individuals with NF1 require additional services in school, and obtaining these services may prove challenging and frustrating.

Risk Assessment

In order to complete an accurate risk assessment, it is crucial to determine whether the disease and/or mutation was inherited or de novo. This can often be accomplished through physical and ophthalmologic examination of the proband’s parents. Alternatively, if a DNA mutation has been identified in the patient, molecular genetic testing can be performed.

If the Mutation is De Novo

Risk for siblings of proband is low (thought to be less than 1%), but remains increased due to the possibility of germline mosaicism (see “Special Considerations”).

If the Mutation is Familial

Apply principles of autosomal dominant inheritance to pedigree. All offspring of an affected parent have a 50% risk

| Table V | Suggestions for Targeted Family History |
|---------|-----------------------------------------|
| Birthmarks or other targeted skin findings |
| Benign growth or tumors |
| Malignant tumor or cancer |
| Significant hearing problem such as hearing loss or ringing of the ears |
| Significant vision problem such as tumor, poor vision or blindness |
| Bone or joint problems (fractures, dislocations, curved spine) |
| Developmental delay, learning disability, ADHD or MR |
| Seizures, epilepsy or other nervous system problems |
| Macrocephaly |

These targeted questions may also aid in differential diagnosis.

| Table VI | Suggestions for Targeted Psychosocial History/Assessment |
|----------|---------------------------------------------------------|
| Level of education |
| Possible barriers to communication, including cultural/language diversity or the presence of learning disabilities |
| Current level of knowledge regarding diagnosis of NF1 |
| Family’s understanding and perception of medical information |
| Previous experiences with NF1, if any |
| Family’s perception of the etiology of NF1 |
| Emotional reaction to the diagnosis of NF1 |
| Family structure and functioning |
| Family and community support systems |
| Coping skills |
| Meaning of a genetic diagnosis for the family, including implications for family planning and parenting |
to inherit the mutation. As indicated, identify nearest genetics/ NF clinic for affected relatives not living in the area.

**Education**

Clinical Features and Natural History

Review the main features of the condition, its natural history, and the typical timeline for the development of features. See “Natural History.”

Inheritance Pattern and Recurrence Risk

NF1 is an autosomal dominant condition. Approximately 50% of NF1 cases are inherited from a parent. The remaining 50% of cases of NF1 are due to a de novo mutation in the proband. This is felt to be due, in part, to the large size of the NF1 gene, which makes it more susceptible to mutation. Penetrance is essentially 100%, but expressivity is variable, even amongst family members.

If neither parent of the proband has NF1, the chance of recurrence is low. However, because of the possibility of germline mosaicism, the recurrence risk is likely somewhat higher than the general population risk (see “Special Considerations”).

Please see “Variants of NF1” for recurrence risks for segmental NF.

Prenatal Testing and Reproductive Options

Prenatal molecular genetic testing is available for families in which the mutation has been identified in the proband. Alternatively, if there are multiple affected family members, and linkage has been established within the family, linkage analysis is an option. In these situations, prenatal diagnosis is possible via chorionic villus sampling (CVS) or amniocentesis. In the vast majority of cases, ultrasound is not useful in the prenatal diagnosis of NF1. There are some reports of prenatal identification of NF1-related abnormalities (Drouin *et al.* 1997; Hoyne *et al.* 1987; McEwing *et al.* 2006). These abnormalities included cardiac and craniofacial anomalies as well as tumors. However, the abnormalities included in these reports were atypical for NF1, and in only one instance was the diagnosis of NF1 considered before birth (McEwing *et al.* 2006).

Given the variability and unpredictable nature of the condition, genetic counseling is critical for a couple considering prenatal testing for NF1. Genetic counseling informs a couple about the signs, course, and genetics of NF1. It also facilitates the discussion of personal, moral, and ethical issues they need to explore in order to make an autonomous decision that meets their needs.

Alternate Risk Reduction Options

In families where a parent is affected and the risk to offspring is 50%, various options can reduce the risk in a future pregnancy. The use of assisted reproductive technology with a donor gamete from an unaffected individual in place of the gamete from the affected parent can greatly reduce the risk to future children. Alternatively, pre-implantation genetic diagnosis (PGD) may be available for couples in which the causative NF1 mutation has been identified or if linkage phase has been established.

Signs and Symptoms that Warrant Immediate Referral and Evaluation

Parents and patients often find it helpful to be informed of what types of symptoms warrant an immediate referral and evaluation.

See Table VII for signs and symptoms warranting emergent evaluation.

**Follow-up**

Management

Management recommendations for patients with NF1 vary between centers and must be tailored to the individual. It is not the intention of this manuscript to address specific management recommendations. It should be noted, however, that management of these patients typically requires a multidisciplinary team. Disciplines that may be involved in the care of a patient with NF1 are listed in Table VIII.

Documentation

Providers are encouraged to thoroughly document all patient interactions. This may be done via a patient summary letter and/or a physician note. In many centers, these two forms of documentation are combined. Please see Table IX for a list of suggested items to be included.

**Special Considerations**

Germline Mosaicism

Germline mosaicism is a recognized phenomenon occurring in a number of dominant genetic disorders and has been observed in NF1 (Lazaro *et al.* 1995; Zlotogora 1998). Therefore, caution must be used when discussing recurrence risks with the parents of a child with an apparently de
A \textit{ novo} case of NF1, even if parental lymphocyte analysis is negative following mutation identification in the proband. Nevertheless, it is estimated that the risk for recurrence due to germline mosaicism is less than 1%.

Consent for DNA Testing

Informed consent for molecular analysis should be obtained from the patient or legal guardian prior to the acquisition of a sample for DNA testing. A consent form from the clinical testing laboratory should be reviewed with the family. Typically, this form describes the limitations and benefits of testing, how results will be reported, and any other potential uses of the specimen.

Table VII Signs/Symptoms Warranting Immediate Referral

| Sign/symptom                                                                 |
|------------------------------------------------------------------------------|
| Pain of unknown etiology                                                     |
| Weakness, numbness, tingling in the extremities                             |
| Change in balance or coordination                                           |
| Change in vision                                                             |
| Change in intensity or frequency of headaches                                |
| Neurofibromas that change rapidly in size and/or color, or cause pain        |
| Abnormal neurologic exam                                                     |
| Sudden onset of hypertension                                                 |
| Regression of cognitive skills or loss of developmental milestones           |
| Significant deviation from individual’s established pattern of growth        |

Table IX Suggested Items to Include in Documentation of NF Visit

| Item to Include                                                                 |
|-------------------------------------------------------------------------------|
| Patient summary letter to include:                                            |
| Diagnostic criteria                                                            |
| Natural history                                                                 |
| Genetics Inheritance                                                          |
| Recurrence risks                                                               |
| Reproductive options                                                          |
| Impression                                                                    |
| Recommendations/follow-up plan                                                |
| Resource information                                                          |
| Contact information for further questions                                      |

Table X Patient Resources

- **Children’s Tumor Foundation (formerly NNFF):** [http://www.ctf.org](http://www.ctf.org); 800-323-7938
- **Neurofibromatosis, Inc:** [http://www.nfinc.org](http://www.nfinc.org); 800-942-6825
- **Understanding NF1:** [http://www.understandingNF1.org](http://www.understandingNF1.org)
- **British Columbia Neurofibromatosis Program:** [http://www.bcnf.bc.ca](http://www.bcnf.bc.ca); 800-385-BCNF (2263)
- **National Society of Genetic Counselors:** [http://www.nsgc.org](http://www.nsgc.org)
- **American College of Medical Genetics:** [http://www.acmg.net](http://www.acmg.net)
- **American Society of Human Genetics:** [http://genetics.faseb.org/ genetics/ashg/ashgmenu.htm](http://genetics.faseb.org/genetics/ashg/ashgmenu.htm)
- **Gene Tests:** [http://www.genetests.org](http://www.genetests.org)

**Patient Resources**

It is important to aid the family in identifying additional sources of support, such as advocacy and support groups, and other families. A list of patient resources is listed in Table X.

**Acknowledgments** The authors are grateful to the many reviewers that contributed their time and expertise to this manuscript. Genetic counselor reviewers included Stefanie Dugan, Lynn Holt, Kory Keller, and Barb Pettersen. Drs. Bruce Korf and Jan Friedman also provided invaluable feedback, as did Mr. Robert Miyamoto, a representative of the Children’s Tumor Foundation. The authors would also like to thank the Genetics Services committee for their guidance throughout the process. Lacy Miles and Dr. Kenneth Grizzle also provided valuable input on the cognitive section. Above all, the authors are appreciative of the families that are directly impacted by neurofibromatosis. We hope that they will benefit from this manuscript.
### Neurofibromatosis Visit Form:

| Category                                      | Details                                      |
|-----------------------------------------------|----------------------------------------------|
| Name                                          | ____________________                        |
| DOB                                           | ____________________                        |
| DOV (if applicable)                           | ____________________                        |
| Age                                           | ____________________                        |
| Medical Record #                              | ____________________                        |
| Referring Physician                           | ____________________                        |
| Primary Care Physician                        | ____________________                        |
| Reason for Referral                           | ____________________                        |
| Chief complaint                               | ____________________                        |

**Medical History:**

- Work-up to date (neuroimaging, radiographs, EEG, audiogram, DNA testing, etc.):
- Developmental History:
- Pregnancy history:
- Labor and delivery history:
- Developmental milestones:
- Surgeries:
- Therapies:

**Current review of systems:**

| Category                                      | Details                                      |
|-----------------------------------------------|----------------------------------------------|
| General Health:                               |                                              |
| Illnesses                                     |                                              |
| Itching                                       |                                              |
| Medications                                   |                                              |
| Café-au-lait spots/Hyperpigmented lesions:    |                                              |
| Neurofibromas/Dermal tumors:                  |                                              |
| Location                                      |                                              |
| Increased growth                              |                                              |
| Pain                                          |                                              |
| Itching                                       |                                              |
| Other                                         |                                              |
| Neurologic:                                   |                                              |
| Headaches                                     |                                              |
| Pain                                          |                                              |
| Tingling/Numbness                             |                                              |
| Seizures                                      |                                              |
| Dizziness                                     |                                              |
| Balance problems                              |                                              |
| Vision:                                       | Blurriness/Double vision                     |
|                                              | Sudden changes                               |
| Fatigue                                       | Scoliosis                                    |
| Coffee intolerance                            | Pseudarthrosis                               |

**Orthopedic:**

- Scoliosis
- Pseudarthrosis

**Physical Exam:**

| Category                                      | Details                                      |
|-----------------------------------------------|----------------------------------------------|
| Height, weight, head circumference            |                                              |
| BP                                            |                                              |
| Dermatologic exam                             |                                              |
| Skeletal exam (long bones, scoliosis)         |                                              |
| Neurologic exam                               |                                              |

**Social History:**

| Category                                      | Details                                      |
|-----------------------------------------------|----------------------------------------------|
| Knowledge of condition:                       | Natural history                              |
|                                              | Genetics                                     |

**Psychosocial assessment:**

- Assessment/Impression:
- Recommendations/Plan:
- Referrals: (see Table VIII)
Additional neuropsychological morbidity? Neuro-oncology, 1(4), 275–281.

Dilts, C. V., Carey, J. C., Kircher, J. C., Hoffman, R. O., Creel, D., Ward, K., et al. (1996). Children and adolescents with neurofibromatosis 1: A behavioral phenotype. Journal of Developmental and Behavioral Pediatrics, 17(4), 229–239.

Drouin, V., Marret, S., Petricolas, J., Euri, D., Vannier, J. P., Fessard, C., et al. (1997). Prenatal ultrasound abnormalities in a patient with generalized neurofibromatosis type 1. Neuropediatrics, 28(2), 120–121.

Dugoff, L., & Sujansky, E. (1996). Neurofibromatosis type I and pregnancy. American Journal of Medical Genetics, 66, 7–10.

Edwards, J. N., Fooks, M., & Davey, D. A. (1983). Neurofibromatosis and severe hypertension in pregnancy. British Journal of Obstetrics and Gynaecology, 90(6), 528–531.

Eliaison, M. J. (1986). Neurofibromatosis: Implications for learning and behaviour. Journal of Developmental and Behavioral Pediatrics, 7, 175–179.

Evans, D., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) Malignant peripheral nerve sheaths, tumors, and neurofibromatosis type 1. Journal of Medical Genetics, 39, 311–314.

Ferner, R. E., Hughes, R. A., & Wenman, J. (1996). Intellectual impairment in neurofibromatosis 1. Journal of the Neurological Sciences, 138, 125–133.

Finucane, B. (1998). Working with women who have mental retardation: A genetic counselor’s guide. Elwyn, Pennsylvania: Elwyn, Inc.

Floyd, A., & Percy-Lancaster, R. (1987). The elephant woman. Neurofibromatosis associated with pseudarthrosis of the humerus. Journal of Bone and Joint Surgery, British Volume, 69, 121–123.

Flueter, U., Bolshauser, E., & Kilchofer, M. (1986). Iris hamartoma as a diagnostic criterion in neurofibromatosis. Neuropediatrics, 17(4), 183–185.

Fois, A., Calisti, L., Balestri, P., Vivarelli, R., Bartalini, G., Mancini, L., et al. (1993). Relationship between café-au-lait spots as the only symptom and peripheral neurofibromatosis (NF1): A follow-up study. European Journal of Pediatrics, 152, 500–504.

Friedman, J. M. (1999a). Vascular and endocrine abnormalities. In J. M. Friedman, D. H. Gutmann, M. MacCollin, & V. M. Riccardi (Eds.), Neurofibromatosis: Phenotype, natural history, and pathogenesis (3rd ed.) (pp. 29–86). Baltimore: The Johns Hopkins University Press.

Friedman, J. M. (1999b). Epidemiology of neurofibromatosis type 1. American Journal of Medical Genetics, 89(1), 1–6.

Friedman, J. M., & Birch, P. H. (1997). Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1,728 patients. American Journal of Medical Genetics, 70, 138–143.

Friedman, J. M., & Riccardi, V. M. (1999). Clinical and epidemiological features. In J. M. Friedman, D. H. Gutmann, M. MacCollin, & V. M. Riccardi (Eds.), Neurofibromatosis: Phenotype, natural history, and pathogenesis (3rd ed.) (pp. 29–86). Baltimore: The Johns Hopkins University Press.

Friedman, J. M., Arbiser, J., Epstein, J. A., Gutmann, D. H., Huot, S. J., Lin, A. E., et al. (2002). Cardiovascular disease in neurofibromatosis 1: Report of the NF1 cardiovascular task force. Genetics in Medicine, 4(3), 105–111.

Gregg, P. J., Price, B. A., Ellis, H. A., & Stevens, J. (1982). Pseudarthrosis of the radius associated with neurofibromatosis. Clinical Orthopaedics, 171, 175–179.

Guran, S., & Safali, M. (2005). A case of neurofibromatosis and breast cancer: Loss of heterozygosity of NF1 in breast cancer. Cancer Genetics and Cytogenetics, 156(1), 86–88.

Gutmann, D. (1999). Abnormalities of the nervous system. In J. M. Friedman, D. H. Gutmann, M. MacCollin, & V. M. Riccardi (Eds.), Neurofibromatosis: Phenotype, natural history, and pathogenesis (3rd ed.) (pp. 29–86). Baltimore: The Johns Hopkins University Press.

Gutmann, D., & Gurney, J. (1999). Other malignancies. In J. M. Friedman, D. H. Gutmann, M. MacCollin, & V. M. Riccardi (Eds.), Neurofibromatosis: Phenotype, natural history, and pathogenesis (3rd ed.) (pp. 231–249). Baltimore: The Johns Hopkins University Press.

Habiby, R., Silverman, B., Listerick, R., & Charrow, J. (1995). Precocious puberty in children with neurofibromatosis type 1. Journal of Pediatrics, 126(3), 346–347.

Hoyme, H. E., Mugrave, S. D., Browne, A. F., & Cleemann, J. J. (1987). Congenital oral tumor associated with neurofibromatosis detected by prenatal ultrasound. Clinical Pediatrics, 26(7), 372–374.

Huson, S. M. (1998). Neurofibromatosis type 1: Historical perspectives and introductory overview. In M. Upadhyaya & D. N. Cooper (Eds.), Neurofibromatosis Type I: From genotype to phenotype (pp. 1–20). Oxford: BIOS Scientific.

Huson, S., Jones, D., & Beck, L. (1987). Ophthalmic manifestations of neurofibromatosis. British Journal of Ophthalmology, 71, 235–238.

Huson, S. M., Compston, D. A., Clark, P., & Harper, P. S. (1989). A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. Journal of Medical Genetics, 26, 704–711.

Hyman, S. L., Shires, A., & North, K. N. (2005). The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology, 65(7), 1037–1044.

Ilgren, B. K., Kimmer-Wilson, L. M., & Stiller, C. A. (1985). Gliomas in neurofibromatosis: A series of 89 cases with evidence for enhanced malignancy in associated cerebellar astrocytoma. Pathology Annual, 20(part1), 331–358.

Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994). Tumour predisposition in mice heterozygous for a targeting mutation in NF1. Nature Genetics, 7(3), 353–361.

Johnson, N. S., Saal, H. M., Lovell, A. M., & Schorry, E. K. (1999). Social and emotional problems in children with neurofibromatosis type 1: Evidence and proposed interventions. Journal of Pediatrics, 134(6), 767–772.

Jones, K. (2005). Smith's recognizable patterns of human malformation. New York: Saunders.

Kayed, L. M., Burke, W., Riccardi, V. M., Bennett, R., Ehrlich, P., Rubenstein, A., et al. (1994). Deletions spanning the neurofibromatosis 1 gene: Identification and phenotype of five patients. American Journal of Human Genetics, 54(3), 424–436.

Kaysel, A. E., & Moore, B. D. (1991). Behavioral phenotype of neurofibromatosis, type 1. American Journal of Human Genetics, 54(3), 424–436.

Keret, D., Bollini, G., Dungl, P., Fixsen, J., Grill, F., & Hefi, F. (2000). The fibula in congenital pseudarthrosis of the tibia: The EPOS multicenter study. Journal of Pediatric Orthopedics Part B, 9, 3–10.

Khosrotehrani, K., Bastuji-Garin, S., Riccardi, V. M., Birch, P., Friedman, J. M., & Wolkenstein, P. (2005). Factors associated with mortality in neurofibromatosis, type 1. American Journal of Medical Genetics, 132(1), 49–53.

Kim, S. E., Heo, E. P., Yoon, T. J., & Kim, T. H. (2002). Segmentally distributed neurofibromatosis associated with adenocarcinoma of the colon. Journal of Dermatology, 29, 350–353.

Kluwe, L., Siebert, R., Gesk, S., Friedrich, R. E., Tinschert, S., Keiner, S., Kreher-Sawatzki, H., et al. (2003). NF1 genotype-phenotype association in neurofibromatosis type 1. Human Mutation, 23(2), 111–116.

Kluwe, L., Tatagiba, M., Fansterer, C., & Mautner, V. F. (2003). NF1 mutations and clinical spectrum in patients with spinal neurofibromas. Journal of Medical Genetics, 40, 638–671.
Korf, B. R. (1992). Diagnostic outcome in children with multiple café-au-lait spots. *Pediatrics*, 90(6), 924–927.

Korf, B. R. (2000). Malignancy in neurofibromatosis type 1. *Oncologist*, 5(6), 477–485.

Korf, B. R., Henson, J. W., & Stemmer-Rachamimov, R. (2005). Case 13-2005: A 48-year-old man with weakness of the limbs and multiple tumors of the spinal nerves. *New England Journal of Medicine*, 352(17), 1800–1808.

Korf, B. R., & Rubenstein, A. E. (2005). *Neurofibromatosis: A handbook for patients, families, and health care professionals* (2nd ed.). New York: NY Thieme Medical Publishers.

Kuorilehto, T., Poyhonen, M., Bloigu, R., Heikkinen, J., Vaananen, M., et al. (2006). Prenatal diagnosis of neurofibromatosis type 1: Sonographic and MRI findings. *Ultrasound in Medicine & Surgery*, 32(2), 165–173.

Lazarro, C., Gaona, A., Lynch, M., Kryuer, H., Ravella, A., & Estivill, X. (1995). Molecular characterization of the breakpoints of a 12-kb deletion in the NFI gene in a family showing germ-line mosaicism. *American Journal of Human Genetics*, 57, 1044–1049.

Leao, M., & da Silva, M. L. (1995). Evidence of central nervous system involvement in Watson syndrome. *Pediatric Neurology*, 12, 252–254.

Lehmacher, T., Gassel, A. M., Rauh, V., Kirchner, T., & Huppertz, H. I. (1994). Neurofibromatosis presenting as a severe systemic vasculopathy. *European Journal of Pediatrics*, 153, 107–109.

Levy, A. D., Patel, N., Abbott, R., Dow, N., Miettinen, M., & Sobin, L. H. (2004). Gastrointestinal stromal tumors in patients with neurofibromatosis: Imaging features with clinicopathologic correlation. *American Journal of Roentgenology*, 183, 1629–1636.

Levy, A. D., Patel, N., Dow, N., Abbott, R. M., Miettinen, M., & Sobin, L. H. (2005). From the archives of the AFIP: Abdominal neoplasms in patients with neurofibromatosis type I: Radiologic–pathologic correlation. *Radiographics*, 25(2), 455–480.

Lin, A. E., Birch, P. H., Korf, B. R., Tenconi, R., Niimura, M., Poyhonen, M., et al. (2000). Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis I. *American Journal of Medical Genetics, 95*, 108–117.

Listernick, R., Charrow, J., Greenwald, M., & Mets, M. (1994). Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. *Journal of Pediatrics*, 125, 632–636.

Listernick, R., Charrow, J., & Gutmann, D. H. (1999). Intracranial gliomas in neurofibromatosis type 1. *American Journal of Medical Genetics*, 89(1), 38–44.

Lubs, M. L., Bauer, M. S., Formas, M. E., & Djokic, B. (1991). Lisch nodules in neurofibromatosis type 1. *New England Journal of Medicine*, 324(18), 1264–1266.

Mazzocco, M. M., Turner, J. E., Denckla, M. B., Hofman, K. J., Scanlon, D. C., & Vellutino, F. R. (1995). Language and reading deficits associated with neurofibromatosis type I: Evidence for a not-so-nonverbal learning disability. *Developmental Neuropsychology*, 11, 503–522.

McEwing, R. L., Joelle, R., Mohlo, M., Bernard, J. P., Hilton, Y., & Ville, Y. (2006). Prenatal diagnosis of neurofibromatosis type 1: Sonographic and MRI findings. *Prenatal Diagnosis*, 26, 1110–1114.

Mensink, K. A., Ketterling, R. P., Flynn, H. C., Knudson, R. A., Lindor, N. M., Heese, B. A., et al. (2006). Connective tissue dysplasia in five new patients with NFI microdeletions: Further expansion of phenotype and review of the literature. *Journal of Medical Genetics*, 43(2), e8.

Messiaen, L. M., Callens, T., Mortier, G., Beye, D., Vandenbroucke, I., Van Roy, N., et al. (2000). Exhaustive mutation analysis of the NFI gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. *Human Mutation*, 15(6), 541–555.

Messiaen, L., Riccardi, V., Peltonen, J., Maertens, O., Callens, T., Karvonen, S. L., et al. (2003). Independent NFI1 mutations in two large families with spinal neurofibromatosis. *Journal of Medical Genetics*, 40(2), 122–126.

Mikol, D., Gulcher, J., & Stefansson, K. (1990). The oligodendrocyte myelin glycoprotein belongs to a distinct family of proteins and contains the HNK-1 carbohydrate. *J Cellular Biology*, 110, 471–480.

Morier, P., Merot, Y., Paccoud, D., Beck, D., & Frenk, E. (1990). Juvenile chronic granulocytic leukemia, juvenile xanthogranulomas, and neurofibromatosis. Case report and review of the literature. *Journal of the American Academy of Dermatology*, 22, 962–965.

Niemeijer, C. M., Arió, M., Basso, G., Biondi, A., Camú, R., Reboli, A., Creutzig, U., & et al. (1997). Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases. *Blood*, 89, 3534–3543.

NIH Consensus Statement Online (1987). *Neurofibromatosis*, 6(12), 1–19.

NIH Consensus Development Conference (1988). Neurofibromatosis: Conference statement. *Archives of Neurology*, 45, 752–756.

North, K. (1993). Neurofibromatosis type 1: Review of the first 200 patients in an Australian clinic. *Journal of Child Neurology*, 8, 395–402.

North, K. (1999). Cognitive Function and Academic Performance. In J. M. Friedman, D. H. Gutmann, M. MacCollin, & V. M. Riccardi (Eds.), *Neurofibromatosis: Phenotype, natural history, and pathogenesis* (3rd ed.) (pp. 162–189). Baltimore: The Johns Hopkins University Press.

North, K., Hyman, S., & Barton, B. (2002). Cognitive deficits in neurofibromatosis I. *Journal of Child Neurology*, 17(8), 605–612.

North, K., Joy, P., Yuille, D., Cocks, N., & Hutchins, P. (1995). Cognitive function and academic performance in children with neurofibromatosis type 1. *Developmental Medicine & Child Neurology*, 37, 427–436.

North, K., Joy, P., Yuille, D., Cocks, N., Hutchins, P., McHugh, K., et al. (1994). Learning difficulties in neurofibromatosis type 1: The significance of MRI abnormalities. *Neurology, 44*, 878–883.

Oguzzan, S., Cinbis, M., Ayter, S., Anlar, B., & Aysun, S. (2004) Familial segmental neurofibromatosis. *Journal of Child Neurology, 19*(5), 392–394.

Ozonoff, S. (1999). Cognitive impairment in neurofibromatosis type 1. *American Journal of Medical Genetics, 89*, 45–52.

Peltomäki, J., Jaakkola, S., Lebow, M., Renvall, S., Risteli, L., Virtanen, I., et al. (1988). Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. *Laboratory Investigation*, 59, 760–771.

Pilmore, H. L., Na Nagara, M. P., & Walker, R. J. (1997). Neurofibromatosis and renovascular hypertension presenting in early pregnancy. *Nephrology Dialysis Transplantation*, 12, 187–189.

Poyhonen, M., Kytola, S., & Leisti, J. (2000). Epidemiology of neurofibromatosis type 1 (NFI) in northern Finland. *Journal of Medical Genetics*, J Med Genet, 37, 632–636.

Raevaara, T. E., Gerdes, A. M., Lomqvist, K. E., Tyberg-Hansen, A., Abdel-Rahman, W. A., Kariola, R., et al. (2004). HNPPC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1. *Genes Chromosomes Cancer*, 40(3), 261–265.

Rasmussen, S. A., Coman, S. D., Ho, V. T., Abbernathy, C. R., Arn, P. H., Weiss, L., et al. (1998). Constitutional and mosaic large NFI gene deletions in neurofibromatosis type 1. *Journal of Medical Genetics*, 35(6), 468–471.

Rasmussen, S. A., & Friedman, J. M. (2000). NFI1 gene and neurofibromatosis 1. *American Journal of Epidemiology, 151*, 33–40.

Rasmussen, S. A., Yang, Q., & Friedman, J. M. (2001). Mortality in neurofibromatosis 1: An analysis using U.S. death certificates. *American Journal of Human Genetics, 68*(5), 1110–1118.
sectional study of 128 cases. *Archives of Dermatology*, 137(11), 1421–1425.

Wu, B., Austin, M. A., Schneider, G. H., Boles, R. G., & Korf, B. R. (1995). Deletion of the entire NF1 gene detected by FISH: Four deletion patients associated with severe manifestations. *American Journal of Medical Genetics*, 59(4), 528–535.

Zhu, Y., & Parada, L. F. (2001). Neurofibomin, a tumor suppressor in the nervous system. *Experimental Cell Research*, 264, 19–28.

Zlotogora, J. (1998). Germ line mosaicism. *Human Genetics*, 102, 381–386.

Zoller, M., Rembeck, B., Akesson, H. O., & Angervall, L. (1995). Life expectancy, mortality and prognostic factors in neurofibromatosis type 1: A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. *Acta Dermato-Venereologica*, 75, 136–140.

Zoller, M. E., Rembeck, B., & Backman, L. (1997). Neuropsychological deficits in adults with neurofibromatosis type 1. *Acta Neurologica Scandinavica*, 95(4), 225–232.

Zvulunov, A., Barak, Y. M., & Metzker, A. (1995). Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. *Archives of Dermatology*, 131(8), 904–908.